1/13
08:03 am
catx
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock.
Low
Report
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock.
1/12
07:00 am
catx
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
High
Report
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
1/9
07:00 am
catx
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Low
Report
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
12/18
07:00 am
catx
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/4
07:00 am
catx
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
High
Report
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
11/24
11:00 am
catx
Perspective Therapeutics (NASDAQ:CATX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Low
Report
Perspective Therapeutics (NASDAQ:CATX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
11/24
08:08 am
catx
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at B. Riley from $12.00 to $11.00. They now have a "buy" rating on the stock.
Neutral
Report
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at B. Riley from $12.00 to $11.00. They now have a "buy" rating on the stock.
11/24
08:06 am
catx
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at UBS Group AG from $18.00 to $7.00. They now have a "buy" rating on the stock.
Neutral
Report
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at UBS Group AG from $18.00 to $7.00. They now have a "buy" rating on the stock.
11/20
07:00 am
catx
Perspective Therapeutics to Participate in Upcoming December Conferences
Medium
Report
Perspective Therapeutics to Participate in Upcoming December Conferences
11/10
04:05 pm
catx
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
Low
Report
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
10/31
07:00 am
catx
Perspective Therapeutics to Participate in Upcoming November Conferences
Low
Report
Perspective Therapeutics to Participate in Upcoming November Conferences
10/24
07:00 am
catx
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
Low
Report
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results